Phase2a Primaquine Dose Escalation Study

NCT01743820 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

81

Enrollment

OTHER

Sponsor class

Conditions

Malaria

Interventions

DRUG: dihydroartemisinin-piperaquine
DRUG: 0.125 mg/kg Primaquine
DRUG: 0.5 mg/kg Primaquine
DRUG: 0.25 mg/kg Primaquine
DRUG: 0.0625 mg/kg Primaquine

Sponsor

University of California, San Francisco

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]